Lexaria Bioscience CORP. (LEXX) — 10-Q Filings

10-Q Filings (7)

• Lexaria Bioscience Files Q1 2026 10-Q — Apr 13, 2026 Risk: medium
  Lexaria Bioscience Corp. filed its quarterly report (10-Q) on April 13, 2026, for the period ending February 28, 2026. The filing includes financial statements
• Lexaria Narrows Q3 Loss Amid Capital Raising Efforts — Jul 14, 2025 Risk: high
  Lexaria Bioscience Corp. reported a net loss of $2,421,983 for the three months ended May 31, 2025, a significant improvement from the $4,520,483 net loss in th
• Lexaria Bioscience R&D Surges in Q2 2025 — Apr 14, 2025 Risk: medium
  Lexaria Bioscience Corp. filed its 10-Q for the period ending February 28, 2025. The company reported total assets of $220 million. For the six months ended Feb
• Lexaria Bioscience Q1 Revenue Drops, Expenses Rise — Jan 10, 2025 Risk: medium
  Lexaria Bioscience Corp. filed its 10-Q for the period ending November 30, 2024. The company reported revenue of $242,198 for the three months ended November 30
• Lexaria Bioscience Q3 2024: $15.8M Revenue, $8.1M Net Income — Jul 12, 2024 Risk: medium
  Lexaria Bioscience Corp. filed its Q3 2024 10-Q report for the period ending May 31, 2024. The company reported $15.81 million in revenue and $8.09 million in n
• Lexaria Bioscience Corp. Files 10-Q for Period Ending February 29, 2024 — Apr 9, 2024 Risk:
  Lexaria Bioscience Corp. (LEXX) filed a Quarterly Report (10-Q) with the SEC on April 9, 2024. Revenue for the six months ended February 29, 2024, was $1,238,76
• Lexaria Bioscience Corp. Files 10-Q for Period Ending November 30, 2023 — Jan 12, 2024 Risk: low
  Lexaria Bioscience Corp. (LEXX) filed a Quarterly Report (10-Q) with the SEC on January 12, 2024. Lexaria Bioscience Corp. reported revenue of $809,165 for the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX